92 related articles for article (PubMed ID: 26502845)
1. Expression of VEGF and its effect on cell proliferation in patients with chronic myeloid leukemia.
Chen H; Shen YF; Gong F; Yang GH; Jiang YQ; Zhang R
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3569-73. PubMed ID: 26502845
[TBL] [Abstract][Full Text] [Related]
2. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
3. Effect of antisense VEGF cDNA transfection on the growth of chronic myeloid leukemia K562 cells in vitro and in nude mice.
Ruan GR; Liu YR; Chen SS; Fu JY; Chang Y; Qin YZ; Li JL; Yu H; Wang H
Leuk Res; 2004 Jul; 28(7):763-9. PubMed ID: 15158098
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.
Krauth MT; Simonitsch I; Aichberger KJ; Mayerhofer M; Sperr WR; Sillaber C; Schneeweiss B; Mann G; Gadner H; Valent P
Am J Clin Pathol; 2004 Apr; 121(4):473-81. PubMed ID: 15080298
[TBL] [Abstract][Full Text] [Related]
5. [Regulation of wild type PTEN gene on Survivin, Xiap and Smac in chronic leukemia cells].
Cheng ZY; Wan JS; Wang YL; Liang LQ; Liang WT; Mu J; Lu X; Pan L
Zhonghua Yi Xue Za Zhi; 2011 Nov; 91(40):2868-72. PubMed ID: 22333553
[TBL] [Abstract][Full Text] [Related]
6. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells.
Zhou HJ; Wang WQ; Wu GD; Lee J; Li A
Vascul Pharmacol; 2007; 47(2-3):131-8. PubMed ID: 17581794
[TBL] [Abstract][Full Text] [Related]
7. [Effects of Scutellaria Barbata on VEGF Expression in K562 Cells].
Shi R; Guo SQ; Liu S; Li ZS; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1339-1342. PubMed ID: 27784353
[TBL] [Abstract][Full Text] [Related]
8. [Anti-angiogenesis of interferon-alpha2b in chronic myeloid leukemia in vitro].
Zhang LM; Yu YZ; Huang ZP; Zhang WS; Dong L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):291-5. PubMed ID: 20416154
[TBL] [Abstract][Full Text] [Related]
9. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
10. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
11. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
[TBL] [Abstract][Full Text] [Related]
12. [SHP-1 gene in the disease progression of chronic myeloid leukemia].
Li Y; Wang X; Yang L; Pan Y; Shang Y; Luo J
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1074-8. PubMed ID: 25543700
[TBL] [Abstract][Full Text] [Related]
13. [Angiogenesis in different clinical phases of chronic myeloid leukemia].
Krasowska-Kwiecień A; Kijowski J; Łukasiewicz E; Sacha T; Foryciarz K; Majka M; Ratajczak MZ; Skotnicki AB
Przegl Lek; 2009; 66(9):471-8. PubMed ID: 21033405
[TBL] [Abstract][Full Text] [Related]
14. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
Li Z; Luo J
Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
[TBL] [Abstract][Full Text] [Related]
15. BCL11A expression in acute phase chronic myeloid leukemia.
Yin J; Zhang F; Tao H; Ma X; Su G; Xie X; Xu Z; Zheng Y; Liu H; He C; Mao ZJ; Wang Z; Chang W; Gale RP; Wu D; Yin B
Leuk Res; 2016 Aug; 47():88-92. PubMed ID: 27285855
[TBL] [Abstract][Full Text] [Related]
16. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
17. Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis.
Godoy CR; Levy D; Giampaoli V; Chamone DA; Bydlowski SP; Pereira J
Braz J Med Biol Res; 2015 Jun; 48(6):509-14. PubMed ID: 25831205
[TBL] [Abstract][Full Text] [Related]
18. [Study on mismatch repair genes of chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro.
Fu FF; Zhu XJ; Wang HX; Zhang LM; Yuan GL; Chen ZC; Li QB
Acta Pharmacol Sin; 2017 Nov; 38(11):1475-1485. PubMed ID: 28836580
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization and prognostic significance of FLT3 in CML progression.
Kim KI; Park J; Ahn KS; Won NH; Kim BK; Shin WG; Yoon SS; Oh JM
Leuk Res; 2010 Aug; 34(8):995-1001. PubMed ID: 20031210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
